Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
Contact Us
AUA Advocacy Communications
10 G Street NE
Suite 600
Washington, D.C. 20002
1-866-RING-AUA (toll-free)
410-689-3810 (direct)
Email
Talking Points Fact Sheet for Novitas/First Coast Proposed LCD
Introduction
- Biomarkers play a vital role in cancer detection and management, similar to drug development in the pharmaceutical industry.
- Robust biomarkers should offer clear benefits alongside clinical and laboratory data.
- Biomarker development involves phases like assay development, validation, clinical studies, and economic validation.
Clinical Utility and Reimbursement
- Biomarker's clinical utility is essential to assess its value in patient management.
- Reimbursement is crucial for a biomarker's viability and accessibility.
- Unreimbursed markers become unavailable, impacting patient care and clinical decision-making.
Recent Changes Proposed by Novitas
- Novitas, a Medicare Administrative Contractor (MAC), proposed changes in coverage criteria for molecular diagnostic tests in an LCD addressing ‘genetic’ testing guidelines.
- The draft LCD suggests an external review model based on limited external databases and guidelines.
- Ensuring clinical needs are met is crucial in coverage decisions.
Importance of Urine-Based Tumor Markers
- Efforts to identify bladder cancer markers for risk assessment and surveillance.
- Clinical scenarios dictate marker type and value.
- Evaluation should align with clinical questions and intended use.
Concerns Regarding Proposed Changes
- Focus on limited guidelines may not address clinical needs comprehensively.
- National respected professional organizations' guidelines should be considered in reimbursement decisions.
- Industry's role in marker development shouldn't be overlooked.
Addressing Concerns About Specific Markers
- Patient demographics impact marker development.
- Concerns about specific tests should consider relevant age data.
- Marker performance varies based on clinical utility.
Balanced Evaluation and Guideline Recommendations
- Comprehensive marker evaluation needed for optimal clinical care.
- Future coverage decisions should consider data, intended use, and expert opinions.
Performance Characteristics of Prostate and Bladder Cancer Markers
- Comparison of performance characteristics for various prostate and bladder cancer markers.
- Demonstrates similarities in performance between covered prostate cancer markers and uncovered bladder cancer markers.
Clinical Evidence and Patient Outcomes
- The Final Local Coverage Determination (LCD) for bladder cancer tests lacks clinical evidence support and contravenes guidelines promulgated by the AUA.
- Non-coverage decision may impact patient outcomes, healthcare costs, and disparities.
Procedural Failures in Issuing the Final LCD
- Novitas' process in issuing the Final LCD lacked transparency and stakeholder contribution and mischaracterizes these biomarker tests.
- Lack of clear description and evidence in the Proposed LCD hindered stakeholder feedback.
- Failure to include practicing urologists' perspectives affected the quality of the Final LCD.
Call to Action
- Novitas should withdraw, delay, or improve the Final LCD or just pull the incorrectly included biomarker tests out of it.
- Proper public review process needed to consider clinical perspectives and patient well-being.
- AUA, LUGPA and AACU are ready, willing and able to assist in a discussion on a separate LCD for these molecular tests.
advertisement
advertisement